Emergent BioSolutions Q4 2022 net loss $88M, revenue $331M (-54% YoY); FY2023 guidance issued

Emergent BioSolutions Inc.

2022-FY EPS reported -$4.47 revenue$1,120,900,000

Q4 2022 total revenues $330.7M vs $723.2M in Q4 2021; net loss $88.0M vs net income $189.3M.
Full year 2022 revenues $1,120.9M (-37% YoY); net loss $223.8M vs net income $230.9M.
FY2023 guidance: revenues $1.1-1.2B, adjusted EBITDA $75-125M, adjusted gross margin 41-44%.
Agreed to sell travel health business to Bavarian Nordic for up to $380M; FDA priority review for NARCAN OTC.
Eliminated 132 positions with annualized savings >$60M; DoD RSDL contract valued up to $379.6M.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

Emergent BioSolutions Inc. reported Full Year 2022 results: revenue $1,120.9, net income $(223.8), EPS $(4.47). Guidance initiated.

Period: Full Year 2022
Revenue: $1,120.9
Net income: $(223.8)
EPS: $(4.47)
Guidance: initiated
Result: reported results

Exact text from the filing

Full Year 2022 vs. Full Year 2021 ($ in millions, except per share amounts) Full Year 2022 Full Year 2021 % Change Total Revenues $1,120.9 $1,792.7 (37)% Net Income (Loss) $(223.8) $230.9 * Net Income (Loss) per Diluted Share $(4.47) $4.27 *

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

Emergent BioSolutions Inc. reported Q4 2022 results: revenue $330.7, net income $(88.0), EPS $(1.76). Guidance initiated.

Period: Q4 2022
Revenue: $330.7
Net income: $(88.0)
EPS: $(1.76)
Guidance: initiated
Result: reported results

Exact text from the filing

Q4 2022 vs. Q4 2021 ($ in millions, except per share amounts) Q4 2022 Q4 2021 % Change Total Revenues $330.7 $723.2 (54)% Net Income (Loss) $(88.0) $189.3 * Net Income (Loss) per Diluted Share $(1.76) $3.50 *

View on SEC.gov

Browse all earnings releases →

Emergent BioSolutions Inc. filing history →

Source: SEC EDGAR

accession 0001367644-23-000024

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.